Thiamine Ion

Thiamine Ion

SCHEMBL5173459

Br.Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.[Cl-]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Thiamine Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.95
TKT P29401 12/20 0.67
TDP1 Q9NUW8 1/20 0.67
KDM4E B2RXH2 1/20 0.66
LMNA P02545 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiamine Ion SCHEMBL29572584 0.99 HSP90AA1 (0.98) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL5173466 0.99 HSP90AA1 (0.98) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL29445547 0.99 HSP90AA1 (0.98) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL10074 0.99 HSP90AA1 (0.98) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL7090274 0.99 HSP90AA1 (0.98) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL9618673 0.98 HSP90AA1 (0.95) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL10636119 0.98 HSP90AA1 (0.95) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL7110640 0.98 HSP90AA1 (0.95) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL10615472 0.98 HSP90AA1 (0.95) HSP90AA1TKTTDP1KDM4ELMNA
Thiamine Ion SCHEMBL9391504 0.98 HSP90AA1 (0.95) HSP90AA1TKTTDP1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180237358-A1 RADIOISOTOPE 18F SUBSTITUTED THIAMINE, AND SYNTHESIS METHOD AND USE THEREOF ZHONGSHAN HOSPITAL FUDAN UNIVERSITY (CN) 2018-08-23 US claimed
EP-3339308-A1 RADIOISOTOPE FLUORINE-18 SUBSTITUTED THIAMINE, SYNTHESIS METHOD THEREFOR, AND APPLICATIONS THEREOF Zhongshan Hospital Fudan University (CN) 2018-06-27 EP claimed
US-8642089-B2 Melt extrusion of salts of active ingredients EVONIK ROEHM GMBH (DE) 2014-02-04 US claimed
EP-1478344-B1 MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS ROEHM GMBH (DE) 2007-05-23 EP claimed
US-20040253314-A1 Melt extrusion of salts of active ingredients ROEHM GMBH (DE) 2004-12-16 US claimed
US-11834425-B2 Full continuous-flow preparation method of vitamin B1 FUDAN UNIVERSITY (CN) 2023-12-05 US disclosed
CN-116283952-A Vitamin B 1 Is a fully continuous flow preparation method 复旦大学 2023-06-23 CN disclosed
US-20230183196-A1 FULL CONTINUOUS-FLOW PREPARATION METHOD OF VITAMIN B1 FUDAN UNIVERSITY (CN) 2023-06-15 US disclosed
US-11248156-B2 Borehole fluid with a thiamine-based shale inhibitor HALLIBURTON ENERGY SERVICES, INC. (US) 2022-02-15 US disclosed
WO-2021066811-A1 BOREHOLE FLUID WITH A THIAMINE-BASED SHALE INHIBITOR HALLIBURTON ENERGY SERVICES, INC. (US) 2021-04-08 WO disclosed
US-20210095179-A1 BOREHOLE FLUID WITH A THIAMINE-BASED SHALE INHIBITOR HALLIBURTON ENERGY SERVICES, INC. (US) 2021-04-01 US disclosed
US-20180237358-A1 RADIOISOTOPE 18F SUBSTITUTED THIAMINE, AND SYNTHESIS METHOD AND USE THEREOF ZHONGSHAN HOSPITAL FUDAN UNIVERSITY (CN) 2018-08-23 US disclosed
EP-3339308-A1 RADIOISOTOPE FLUORINE-18 SUBSTITUTED THIAMINE, SYNTHESIS METHOD THEREFOR, AND APPLICATIONS THEREOF Zhongshan Hospital Fudan University (CN) 2018-06-27 EP disclosed
US-8642089-B2 Melt extrusion of salts of active ingredients EVONIK ROEHM GMBH (DE) 2014-02-04 US disclosed
US-20040253314-A1 Melt extrusion of salts of active ingredients ROEHM GMBH (DE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183196-A1 FULL CONTINUOUS-FLOW PREPARATION METHOD OF VITAMIN B1 SLC19A2, VKORC1, VKORC1L1 HSP90AA1 3116/4885TKT 860/4885TDP1 4866/4885
US-20180237358-A1 RADIOISOTOPE 18F SUBSTITUTED THIAMINE, AND SYNTHESIS METHOD AND USE THEREOF SLC19A2, SLC35E1, SLC46A1 HSP90AA1 1905/4885TKT 15/4885TDP1 1471/4885
US-11834425-B2 Full continuous-flow preparation method of vitamin B1 SLC19A2, CYP2S1, CBS HSP90AA1 3137/4885TKT 111/4885TDP1 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.